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Intradermal injection of low dose 
human regulatory T cells inhibits 
skin inflammation in a humanized 
mouse model
Sija Landman  1, Vivian L. de Oliveira1, Piet E. J. van Erp2, Esther Fasse1, Stijn C. G. Bauland3, 
Irma Joosten1 & Hans J. P. M. Koenen1
Recent regulatory T cell (Treg) based clinical trials support their therapeutic potential in transplantation 
and auto-inflammatory diseases. However, large numbers of Treg are needed to accomplish therapeutic 
efficacy. Local injection at the site of inflammation (targeted delivery) may lower the numbers needed 
for therapy. We evaluated if local delivery of low numbers of human Treg by intradermal injection was 
able to prevent skin inflammation, using the humanized mouse huPBL-SCID-huSkin allograft model. A 
dose of only 1 × 105 freshly isolated, non expanded Treg injected intradermally in close proximity to the 
transplanted human skin prevented inflammation of the grafted tissue induced by 4 × 107 IP injected 
human allogeneic PBMCs, (ratio Treg:PBMC = 1:400), as indicated by the inhibition of epidermal 
thickening, sustained Keratin-10 expression, the absence of Keratin-16 up regulation and prevention 
of human CD3+ T cell influx. A concomitant reduction of human T cells was observed in lymph nodes 
and spleen of the mice. Injection of Treg at the contralateral side was also shown to inhibit skin 
inflammation, suggesting that the inflammatory response was regulated both locally and systemically. 
In conclusion, local application of Treg may be an attractive way to suppress inflammation in vivo 
without the need for prior ex vivo expansion.
Regulatory T cells (Treg) are important in maintaining immune homeostasis1. Due to their potential as immune 
modulators, Treg are studied widely for therapeutic use in order to control unwanted immune responses and to 
promote tolerance in transplantation, autoimmunity, and chronic inflammatory diseases2–5.
Recently, a promising effect of Treg therapy with expanded FOXP3+ Treg in the prevention of 
graft-versus-host-disease, a common complication after allogeneic stem cell transplantation, was demonstrated6,7. 
Currently, Treg therapy is also tested in solid organ transplantation. In living donor liver transplantation, a pilot 
study with ex vivo expanded Treg was shown to be effective and to induce operational tolerance8. The ONE study 
investigates the use of expanded Treg after living donor kidney transplantation (clinicaltrials.gov NCT02085629). 
These phase I/II clinical trials aim to find the optimal dose and dosing regimen as well as to characterize the best 
Treg subtype and ex vivo expansion protocol. All these studies make use of ex vivo Treg expansion protocols, 
and struggle to consistently obtain sufficient cell numbers. Also in autoimmunity and chronic inflammatory 
diseases, the first trials are underway. Promising results were obtained in small scale phase I/II clinical trials in 
type 1 diabetes (T1DM)9,10, Crohn’s disease11 and uveitis12. Treg function in these diseases is often hampered and 
optimal isolation, expansion, and injection protocols are under study13. As to our knowledge, no clinical studies 
so far have been performed in skin inflammatory diseases, like psoriasis, while also here Treg therapy may hold 
promise14.
Currently, in clinical trials, typically around 1–10 × 106 Treg/kg are infused systemically2. This amount of cells 
cannot be obtained by simple blood collection and therefore Treg have to be expanded. Different ex vivo expan-
sion protocols are being studied15–18, however, expansion has its disadvantages. Expansion is time consuming and 
limits the possibilities for use in acute cases. Furthermore, due to their plasticity, Treg can convert into potentially 
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inflammatory IL-17 producing cells, which is more likely to occur when cells are expanded19. When cells are given 
systemically/ IV, the majority of cells is lost or does not reach the site of inflammation. Therefore, we investigated 
the possibility of a more targeted delivery approach, with injection of Treg in or close to the site of inflammation. 
This approach might require lower Treg numbers compared to systemic infusion and exclude the need for expan-
sion. To test our hypothesis we made use of a humanized mouse model for skin inflammation. The choice for skin 
as a model to explore local application of Treg was made on the basis that it is easy accessible and supported by 
the fact that Treg in skin are highly important for tissue repair and reduction of skin inflammation20. We used the 
so-called huPBL-SCID-huSkin allograft model.
In this model, human skin is transplanted to immune deficient mice and allowed to heal for 3 weeks. 
Thereafter, allogeneic peripheral blood mononuclear cells (PBMC) are infused by intraperitoneal (IP) injection. 
In time (2–3 weeks) an immune response mainly consisting of human T cells establishes as demonstrated by the 
influx of human T cells in the skin, peripheral blood and secondary lymphoid organs21–23. This human-skin allo-
graft model resembles human plaque-type psoriasis at multiple levels, as indicated by erythema and skin thicken-
ing, acanthosis, parakeratosis and psoriasis like rete ridges, increased expression of hBD-2, K16 and reduced K10 
expression and a strong influx of T cells21. This model also reveals similarities with the graft-versus-host-disease 
(GVHD) of the skin that might occur after stem cell transplantation, including increased expression of Elafin by 
keratinocytes21, which has been shown to be a biomarker of GVHD of the skin21,24.
In a variety of humanized mouse models, including our own, systemic injection of high numbers of Treg, i.e. 
Treg:PBMC ratio’s of 1:5/1:10, was required to inhibit the inflammatory response against islet25, arterial26, and 
skin15,21 allografts. Previously it has been demonstrated that following Treg infusion in a similar humanized skin 
allograft BALB/c Rag2−/−cγ−/− model that at a Treg:PBMC ratio of 1:10 the immunosuppressive effect of Treg 
infusion was lost27. Using our humanized mouse allograft SCID/beige model similar observations were made 
(data not shown).
Here, we demonstrate that low numbers of Treg applied locally can successfully dampen skin inflammation. 
Where possible, this finding paves the way for the development of protocols that focus on local delivery, without 
the need for prior ex vivo Treg expansion.
Results
Intradermal injection of low dose freshly isolated Treg inhibits skin inflammation. To assess the 
effectiveness of intradermally applied Treg in the inhibition of human skin inflammation, we first determined 
the minimal amount of intradermally injected Treg that were needed to inhibit epidermal thickening as part of 
the inflammatory process in the huPBL-SCID-huSkin allograft model. A range of 2.5–10 × 104 high purity FACS 
sorted human Treg were injected intradermally together with 4 × 107 allogeneic IP injected PBMC. FACS sorted 
Treg were typically >96% pure CD4+CD25hi cells and more than 90% of these cells were FOXP3+ (Fig. 1A). 
IP injection of human allogeneic PBMC alone induced epidermal thickening of the grafted human skin (PBS 
126.0 µm (36–163 µm), PBMC 580.0 µm (276–580 µm), p = 0.0765), as also described previously21. We found 
that at least 7.5–10 × 104 Treg were needed to inhibit this process (thickness: 272 µm (244–301 µm) and 269,5 µm 
(214–325 µm), respectively (Fig. 1B)).
Based on these results, we selected a dose of 1 × 105 intradermally injected Treg and 4 × 107 IP injected 
PBMC (a Treg:PBMC ratio of 1:400) to be used for subsequent experiments. Intradermal injection of this low 
dose of Treg prevented hyperkeratosis (Fig. 2A,E) (PBS 163.0 µm (36–212 µm), PBMC 301.3 µm (142–580 µm), 
PBMC + Treg 214.0 um (64–335.8 µm) (PBMC vs PBMC + Treg p = 0.0395), and prevented parakeratosis and 
acantosis, as well as the inflammation induced reduction of K10 expression (Fig. 2B,F) (PBS = 50.9% (24.6–
67.2%), PBMC = 4.4% (0–27.3%), PBMC + Treg = 44.2% (5.6–65.2%) (PBMC vs PBMC + Treg p = 0.002)). 
Expression of K16 en hBD2 was analysed by immunofluorescence, and quantified by measuring the median 
fluorescent expression levels (MFI) in the epidermis (Fig. 2C,D). Low dose Treg injection inhibited the inflam-
mation induced expression (MFI) of K16 (Fig. 2C,G) (PBS = 1883 (1609–2051), PBMC = 5267 (3950–6543) and 
PBMC + Treg = 4056 (2021–6993), PBS vs PBMC p = 0.0014; PBMC vs PBMC + Treg p = 0.0252) and hBD2 
(Fig. 2D,H) (PBS = 1089 (1049–1153), PBMC = 1364 (1220–2005) and PBMC + Treg = 1221 (1116–1333), PBS 
vs PBMC p = 0.0014, PBMC vs PBMC + Treg p = 0.0039).
Skin inflammation in the huPBL-SCID-huSkin allograft model is largely driven by the influx of human T cells 
into the dermis21. Intradermal injection of low dose Treg significantly inhibited the influx of human CD3+ T-cells 
in the dermis (PBS = 282 (117–373) cells/mm2, PBMC = 1700 (842–4197) cells/mm2 and PBMC + Treg = 784 
(142–3202) cells/mm2, PBS vs PBMC p = 0.0014, PBMC vs PBMC + Treg, p = 0.0252) (Fig. 3A,D). We observed 
that the injection of Treg did not influence the influx of CD8 + T cells (Fig. 3B,E), (PBS 0–359.3 cells/mm2 (median 
0 cells/mm2), PBMC 0–389.5 (median 56.69/mm2), PBMC + Treg 0–437.8 cells/mm2 (median 190.6 cells/mm2); 
hence the observed reduction in CD3+ cells is likely due to a reduced influx of CD4+ T cells. Although we did 
not observe a significant increase in the absolute number of human FOXP3 + Treg in the human dermis after 
injection of Treg (Fig. 3C,F) (PBMC 0–154.7 cells/mm2, (median 38.6 cells/mm2), PBMC + Treg 0–125.1 cells/
mm2, (median 72.1 cells/mm2)), a significant increase was found in the ratio of CD3:FOXP3(Fig. 3G) (PBMC 
median ratio 49:1, PBMC + Treg median ratio 11:1, p = 0.0082). This suggests that intradermal injection of Treg 
in the mouse skin leads to a relative increase in FOXP3+ cells in the human dermis and local inhibition of the 
inflammatory response.
Having established that intradermal injection of Treg in close proximity to the inflamed skin is effective, we 
next wondered if this close proximity is actually required to mediate the inhibitory effect of the Treg. Thus we 
set out to inject Treg at the contralateral (CL) side of the skin graft. Data are presented as the right column of 
Figs 2 and 3. The data show that also contralateral injection results in reduced epidermal thickening (epithelial 
thickness 111.2–421.4 µm (median 191 µm) p = 0.0182), restoration of the K10/K16 conversion (K10 = 12.5–
64.8% (median 13.10), p = 0.05 and K16 MFI = 1985–3749 (median 2867) p = 0.0182, down regulation of hBD2 
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(MFI = 1098–1142 (median 1120), p = 0.0182), and reduced cell influx (CD3 = 185.5–460.6 cells/mm2 (median 
323.1 cells/mm2), p = 0.0182.
Low dose intradermal injection of Treg affects systemic repopulation of human lympho-
cytes. To assess whether next to local effects intradermal injection of Treg also exerted systemic effects we 
analyzed secondary lymphoid organs. After harvesting and processing spleen and draining lymph nodes (LN), 
the obtained cells were analyzed by flow cytometry. Following intraperitoneal injection of human-PBMC in 
the skin-transplanted immunodeficient SCIDbeige mice there is clear expansion of the infused T cells that is 
considered as repopulation, which can be visualized measuring the expression the human leukocyte marker 
anti-human-CD45 by flow cytometry21,28. IP injection of 4 × 107 PBMC resulted in systemic repopulation of 
human CD45+ lymphocytes in the mouse spleen and LN, which is in line with previous findings15,21. We observed 
an average of 7.4% human CD45+ cells in the LN and 0.63% CD45+ cells in the spleen. Intradermal injection 
of 1 × 105 Treg inhibits human lymphocyte repopulation in LN (2,28%, NS.) and spleen (0.2%, p = 0.0111). 
(Fig. 4A,B). Although the percentages of human CD4+ and CD8+ T cells within the CD45+ population were 
similar in LN and spleen (Fig. 4C,D), the percentage of CD45+CD4+FOXP3+ T cells were significantly increased 
in LN and spleen following intradermal Treg injection. (LN 15.6% in PBMC, 29.0% in PBMC + Treg p = 0.0175; 
Spleen 11.7% in PBMC, 29.6% in PBMC + Treg p = 0.0175) (Fig. 4E). Taken together, these results show that low 
dose intradermal Treg injection influences not only the local, but also systemic inflammatory response in the 
huPBL-SCID-huSkin allograft model.
Discussion
Severe inflammatory skin diseases like severe psoriasis are often treated with biologics, which target the proin-
flammatory cytokine signaling pathways of TNFα, IL-23 and IL-17. Although these biologics are very successful 
in the treatment of psoriasis, a substantial group of patients does not respond to this treatment. This urges the 
quest for novel treatment modalities. Treg-based immune therapy might be a future option. Recently, successful 
clinical trials with Treg have been conducted in stem cell and solid organ transplantation as well as in (auto)
inflammatory diseases such as type-1 diabetes and uveitis9,12,29–32. Also Treg based therapy is considered in the 
Figure 1. CD4+ CD25high gating strategy and dose response curve of freshly isolated non-expanded Treg. (A) 
Gating strategy for sorting CD4+ CD25high Treg from isolated CD4+ T cells, and flow cytometric analysis of 
FOXP3 expression after sorting. (B) Dose-response curve showing epidermal thickness of human transplanted 
skin in the huPBL-SCID-huSkin allograft model upon IP PBMC injection without or with intradermal injection 
of increasing doses of Treg (X-axis). Every dot in the figure represents data from a single mouse.
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treatment of refractory Crohn’s disease11. An advantage of Treg therapy might be realization of infectious immune 
suppression, known as a self-perpetuating mechanism of immune suppression. Biologics on the other hand need 
to be administered life-long.
Figure 2. Inhibition of epidermal thickening, sustained K10 expression and absence of K16 and hBD2 up 
regulation in the epidermis of the human skin after intradermal Treg injection. Representative histology of 
human skin grafts from SCID beige mice 21 days after IP injection with huPBMC with or without intradermal 
low dose Treg injection showing: (A) epidermal thickness (HE staining), and the expression of (B). K10 (IHC), 
(C). K16 and (D). hBD2 (IF). The cell injection conditions are indicated at the top. The most right panel shows 
the effect of injecting Treg at the contralateral side of the transplanted skin (E–H). Cumulative data showing 
the median of the epidermal thickness, percentage K10, and median expression levels (MFI) of K16 and hBD2. 
Every dot in the figure represents a single mouse experiment (n = 3–10). Statistical significance was analyzed by 
the Mann Whitney U test. *P < 0.05. **P < 0.01.
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The application of Treg based therapy is studied in clinical transplantation and auto-inflammatory disease2,4, 
typically using intravenous infusion of large numbers of Treg (e.g. 1–10 million cells/kg in the ONE study33). To 
obtain high numbers of Treg these cells have to be expanded ex vivo prior to use13,15–18. Ex vivo Treg expansion is 
a critical and laborious step that also introduces the risk of Treg conversion into pro-inflammatory cytokine pro-
ducing cells19. We here hypothesized that targeted delivery of Treg at the site of inflammation might require lower 
numbers of Treg, thereby circumventing large scale ex vivo expansion with its drawbacks. In the present study, we 
demonstrate that intradermal injection of very low numbers of freshly isolated, non-expanded, human Treg can 
inhibit skin inflammation in the humanized mouse huPBL-SCID-huSkin allograft model.
Figure 3. Intradermal Treg injection inhibits the T cell influx and promotes FOXP3+ cells in the human 
dermis. Representative histology of human skin grafts from SCID beige mice 21 days after IP injection with 
huPBMC with or without intradermal low dose Treg injection showing (A). CD3, (B). CD8 and (C). FOXP3 
cell counts per mm2 in the dermis (D–F). Cumulative data figures showing the median of the cells counts. (G) 
Ratio of CD3:FOXP3 in the dermis. Every dot in the figure represents a single mouse experiment (n = 3–10). 
Statistical significance was analyzed by the Mann Whitney U test. *P < 0.05. **P < 0.01.
www.nature.com/scientificreports/
6SCIeNTIfIC REPORTS |  (2018) 8:10044  | DOI:10.1038/s41598-018-28346-5
Systemic administration of Treg, either by intravenous or intra peritoneal injection, may well require high 
numbers of Treg because the injected cells will be distributed throughout the circulation and tissues and as a 
consequence a substantial part of the infused cells will be lost34. This appears not to be the case when Treg are 
injected locally, as we demonstrate here. As for now, we can only speculate why intradermal Treg injection is so 
efficient. The skin is a complex organ, that next to its strong barrier function, has an important role in the immune 
defence35 and reveals active trafficking of immune cells such as antigen presenting cells and T cells36,37. The local 
skin environment facilitates optimal migration to the draining lymphoid organs and control of the immune 
response. This is supported by skin based vaccination strategies that in humans resulted in highly efficient immu-
nization38. Interesting in this respect are intradermal dendritic cell (DC) vaccination trials that resulted in supe-
rior antitumor T-cell induction and faster transit to draining LN39–42. Since intradermal Treg injection in our 
model led to inhibition of systemic human immune cell reconstitution, it is likely that intradermally injected 
Treg travel towards the draining LN and regulate the immune response at the level of the secondary lymphoid 
organs. The notion of a more systemic immune suppressive effect is further strengthened by our observation 
that injection of Treg at the contralateral side of the animal, and thus far distant from the human transplant, also 
Figure 4. Intradermal Treg injection prevents repopulation of huPBMC and results in a relative increase of 
CD4+ FOXP3+ cells in the secondary lymphoid organs. (A) Representative flow cytometry pictures showing 
human CD45 expression in single cell suspensions from draining LN and spleen from SCID beige mice 21 days 
after IP injection with huPBMC with or without intradermal low dose Treg injection. Cumulative data figures 
showing the median percentages of human (B). CD45+ cells and (C). CD4+, (D). CD8+, (E) CD4+ FOXP3+ 
cells within the CD45+ cells in draining in LN (upper row) and spleen lower row). N = 3–10 Statistical 
significance was analyzed by the Mann Whitney U test. *P < 0.05.
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inhibited inflammation of the graft. Although local intradermal injection of low Treg numbers seems to impair 
the systemic immune response, we advise scientist interested in the suppressing systemic inflammation to validate 
these findings.
Although our current work shows for the first time that small numbers of intradermally injected Treg inhibit 
inflammation in vivo, it appeared technically challenging to demonstrate where and how these little numbers 
of Treg exerted in vivo suppression. In our current work we focused on biodistribution analysis by both fluo-
rescence and radioactive tracking of the injected Treg. CFSE-based cell labeling is possibly of interest for short 
term-tracking (ie 1–3 days), but appeared not suited to for long-term (3 weeks) biodistribution analysis of intra-
dermal injected Treg (data not shown). Additionally we focused on radioactivity-based biodistribution analysis 
and survival of the injected Treg by radioactive 111Indium labeling of the cells combined with whole body scan 
SPECT-CT imaging. However, after multiple endeavors of labeling of human Treg with 111Indium-oxinate the 
labeling procedure turned out to be challenging; the labeling efficiency of the isolated Treg was poor and their 
survival after the labeling was low and unfortunately did not allow for biodistribution and survival analysis. 
Future studies should focus on optimizing Treg labeling and in vivo tracking procedures in order to demonstrate 
the survival and biodistribution of the intradermally injected cells and to further demonstrate their mechanism 
of action’.
In our model, we have been infusing Treg in the skin with the idea to prevent skin inflammation. The skin is 
an easily accessible organ, the question is if local delivery of Treg is feasible in case of solid organ transplantation 
or autoimmune disease such as type-1 diabetes (T1D) or Crohn’s disease, which are obviously less accessible. Our 
data suggests that intradermal Treg infusion promotes Treg migration to the secondary lymphoid organs and 
controls the immune response there. In fact, in human LNs we have previously demonstrated that Treg are acti-
vated and that a substantial number of the Treg is proliferating43. This suggests that secondary lymphoid organs 
are a physiological platform to organize Treg output. In case of Treg-based therapy in organ transplantation, T1D 
or Crohn’s disease intra nodal injection of Treg in the draining LNs might facilitate local control of the immune 
response. Intra nodal injection of dendritic cells is already successfully clinically applied in tumor vaccination 
protocols44.
Taken together, targeted intradermal administration of low dose Treg seems to offer a feasible approach for 
Treg therapy that omits the need for laborious and costly ex vivo Treg expansion and reduces the risk of Treg 
plasticity.
Materials and Methods
Humanized mouse model; huPBL-SCID-huSkin allograft model. The huPBL-SCID-huSkin allo-
graft model used in this study is described in detail by de Oliveira et al.21. Female B17.B6-PrkdcscidLystbg/Crl 
(SCID beige) mice, 8–12 weeks old (Charles River Breeding Laboratories) were transplanted with human skin 
from healthy individuals obtained after abdominal plastic surgery at Bauland kliniek (Mill, the Netherlands). 
After healing of the human skin (21 days), 4 × 107 PBMCs were injected IP in the absence or presence of 
2.5 × 104–1 × 105 intradermally injected Treg. All animal experimental procedures were in accordance with the 
international welfare guidelines and approved by the institutional animal ethical committee of the Radboud 
University in Nijmegen (DEC 2013–023). The use of human skin and peripheral blood were approved and in 
accordance with the regulations set by the Medical Ethical Committee for human research of the Radboudumc. 
Human skin and buffy coats (Sanquin Blood Bank, Nijmegen, the Netherlands) were obtained from healthy 
donors, who gave written consent for scientific use according to the declaration of Helsinki. All experiments were 
performed in accordance with relevant guidelines and regulations.
Mice were sacrificed 3 weeks after cell injection by orbita extraction followed by cervical dislocation. 
Terminating the experiment after 3 weeks allows us to study skin inflammation before skin is rejected. In rare 
cases rejection with GVHD like symptoms, like excessive proliferation of PBMCs in LN and/or spleen, are seen. 
These mice are excluded from the analysis after ending the experiment with the following exclusion criteria: > 5% 
CD45+ cells in spleen and/or >20% CD45+ cells in LN as measured with FACS.
Regulatory T cell injection. PBMCs where isolated from buffy coats using ficoll density gradient isola-
tion (Lymphoprep, Nycomed-Pharma AS, Oslo, Norway). To isolate human CD4+ CD25hi Treg, first CD4+ 
T cells were enriched using the RosetteSepTM (StemCell™ Technologies, Vancouver, Canada) human CD4+ T 
cell enrichment cocktail according to the manufacturers description, followed by high purity CD4+CD25high cell 
sorting using a BD FACSAria cell sorter (BD Biosciences, Erembodegem, Belgium). For this purpose, cells were 
labeled with CD4-BV510 and CD25-Pe-Cy7(M-A251; BD Biosciences, New Jersey, USA). This typically resulted 
in >96% pure CD4+CD25hi cells and more than 90% of these cells were FOXP3+. Without ex vivo expansion, 
high purity sorted Treg (or PBS, vehicle control) were injected intradermally in the mouse skin at 4 spots closely 
around the human skin graft, in a total volume of 100 µl PBS.
Histology. Human skin grafts were fixed in neutral buffered 4% formalin (Mallinckrodt Baker Inc, Deventer, 
the Netherlands) for 4 hours and processed in a Tissue-Tek VIP tissue processor and embedded in paraffin. 6 µm 
sections of human skin transplants were stained with hematoxillin-eosin (HE) or processed for either immuno-
histochemical (IHC) or immunofluorescent (IF) staining. Keratinocyte differentiation was analyzed using anti-
bodies against keratin 10 (K10, IHC, RKSE60, Sanbio, Uden, The Netherlands) and keratin 16 (K16, IF, LL025, 
BioTrend, Koln, Germany). Anti-Human β-defensin 2 (hBD2, IF, Ab9871, Abcam, Cambridge, UK) was used 
as a marker for the innate skin inflammatory response. For the detection of T cells the following antibodies 
were used: anti-CD3 (IF, A0452, DAKO, Glostrup, Denmark), anti-CD8 (IHC, 144B, Dako), and anti-FOXP3 
(IHC, PCH101, eBioscience, ThermoFisher Scientific, Waltham, USA). For IHC, antibody stainings were vis-
ualized using the EnVision + system-HRP (Dako) combined with 3,39-diaminobenzidine tetrahydrochloride 
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(DAB, brown metal enhanced DAB 1856090 Thermoscientific) or using the Labeled Streptavidin Biotin method 
(Universal LSAB Kit/AP; Dako) combined with Permanent Red (Dako). For IF, nuclei were stained and embed-
ded using DAPI (fluormount-G with DAPI, eBioscience). The secondary antibody for K16 was AF488-conjugated 
donkey anti-mouse IgG (ThermoFisher); for hBD2 AF546-conjugated donkey anti-goat (ThermoFisher), and for 
CD3 AF647-conjugated donkey anti-rabbit (ThermoFisher). Sections were photographed using a microscope 
(AxioImager M2; Zeiss, Sliedrecht, the Netherlands) and a high resolution color camera for bright field micros-
copy (AxioCam 105 color, Zeiss) and a high resolution b/w camera for multichannel fluorescence microscopy 
(AxioCam 503 Mono).
Image analysis of histology. Mean epidermal thickness was calculated using AxioVision software version 
4.8 (Zeiss) or ZEN blue edition version 2.3 (Zeiss) as epidermal area divided by epidermal surface length. For 
quantification of K10 positive cells, images were saved at 10x objective magnification. The total epidermal area 
and K10 positive area were measured using ImageJ in the region of interest (ROI) and displayed as % K10 pos-
itive epidermal area. To determine the number of CD8+ and FOXP3+ cells, representative pictures were made 
at 10 × objective magnification. To quantify the cell counts in the dermis, a representative ROI was drawn from 
the lowest epidermal papilla till 300 µm dept in the dermis. Cells in this region were counted and expressed as the 
number of cells per mm2. For quantification of K16 and hBD2 positive cells, images were made at 20x objective 
magnification. The median fluorescent intensity (MFI) in epidermis was determined using ZEN blue (Zeiss). 
CD3 + cells were counted in the dermis using ZEN blue and expressed as the number of cells per mm2.
Flow Cytometry. Spleen and mesenteric lymph nodes (LN) were harvested and cells were obtained by mash-
ing over a 40 µm filter. Single cell suspensions of spleen and LN were phenotypically analyzed using a Navios 
multi-color flow cytometer (Beckman-Coulter, Mijdrecht, the Netherlands). Human leukocytes were identified 
using an antibody directed against the common human surface leukocyte marker CD45 (anti-human-CD45-KO 
(J33, Beckman-Coulter). For cell-surface staining of human CD4 and CD8 T cells, the following antibodies 
were used: anti-CD4-PC5.5 (13B8.2, Beckman Coulter), and anti-CD8-APC-AF700 (B9.11, Beckman-Coulter). 
For intracellular staining with anti-FOXP3-e450 (PCH101, eBioscience), cells were fixed and permeabilized by 
fix-perm treatment (eBioscience) according to manufacturers instruction. Data were analyzed using Kaluza soft-
ware version 1.5a (Beckman-Coulter) and gates were set based on single staining and FMOs (Supplemental Fig. 1)
Data and Statistics. Statistical analysis was performed using GraphPad Prism software version 5.03 
(Graphpad Software Inc., San Diego, US). The median of the data points is displayed unless mentioned otherwise. 
Groups were compared using Mann Whitney U test. Differences with a p-value of <0.05 were considered signif-
icant and are indicated with an asterisk (*). p < 0.01 is indicated as**.
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